Zimmer Biomet, US98956P1021

Zimmer Biomet promotes leaders. UBS sets USD 120 target for Zimmer Biomet stock

Published on 10/06/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 2.18 billion, up 4.80 percent year over year. Zimmer Biomet stock costs EUR 81.37 on October 6, 2026 after EUR 81.06, plus 0.38 percent.

Schwarzweiß-Reportagefoto einer Technikerin bei der Prüfung von Hüftprothesen
Zimmer Biomet US98956P1021 dokumentiert Technikerin bei Prüfung von Hüftprothesen-Komponenten in Schwarzweiß-Reportage-Aufnahme heute, Illustration mit AI erstellt.

Zimmer Biomet (ISIN US98956P1021) announced leadership promotions effective October 1, 2026, while UBS reaffirmed a Buy rating and a USD 120.00 price target on August 6, 2026. As MarketScreener reports, Gary Campbell became President, Americas, Brian Hatcher took charge of several business groups, and Bradley Kessler became President, Americas - Robotics, Technology and Data.

Three leaders take new roles

The appointments are part of Zimmer Biomet's commercial restructuring, with Kevin Thornal leaving the company after a transition period ending September 30, 2026. The changes place robotics, technology, data and several procedure-focused businesses under newly promoted executives.

Second-quarter revenue rose 4.80 percent

Zimmer Biomet reported USD 2.18 billion in revenue for the second quarter of 2026, up 4.80 percent from the same quarter a year earlier, according to MarketBeat. Adjusted earnings per share reached USD 2.07, exceeding the USD 2.01 consensus by USD 0.06, while fiscal 2026 adjusted earnings-per-share guidance stood at USD 8.47 to USD 8.59.

Structured financial data show second-quarter 2026 operating cash flow of USD 447.8 million and revenue of USD 2.177 billion. The figures point to a business generating cash while management reshapes its commercial organization.

Next results are scheduled for November 4

Zimmer Biomet will publish its third-quarter 2026 results on November 4, 2026, with a conference call scheduled for 8:30 a.m. ET, according to StockTitan. The release is due at 6:30 a.m. ET, giving investors a defined checkpoint for the leadership changes and the 2026 outlook.

EUR 81.37 in afternoon trading

Zimmer Biomet stock was trading at EUR 81.37 at Lang & Schwarz on October 6, 2026 at 3:33 p.m. CEST, up 0.38 percent versus the prior close of EUR 81.06 on October 5, 2026. On the NYSE, the stock was last at USD 91.14 on October 6, 2026 at 9:39 a.m. ET, against a 52-week range of USD 79.12 to USD 106.88.

The further course of trading is shown by the continuously updated real-time quote of Zimmer Biomet stock.

Zimmer Biomet stock facts

  • Company: Zimmer Biomet Holdings, Inc.
  • ISIN: US98956P1021
  • Ticker: ZBH
  • Primary exchange: NYSE
  • Price Lang & Schwarz as of October 6, 2026 at 3:33 p.m. CEST: EUR 81.37
  • Change versus prior close: plus 0.38 percent
  • Prior close Lang & Schwarz October 5, 2026: EUR 81.06
  • Market capitalization: USD 17.6 billion as of October 6, 2026
  • Sector / Industry: Healthcare / Medical Devices
  • Next earnings date: November 4, 2026

More news and analyses on Zimmer Biomet stock

Disclaimer...

en | US98956P1021 | ZIMMER BIOMET | boerse | 70242880 | bgmi